2. Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark;
3. Fu Wai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China;
4. Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, UK;
5. Medizinische Klinik I, Herz-Thorax Zentrum, Klinikum Fulda, Fulda, Germany
6. Shanghai MicroPort Medical (Group) Co., Ltd. Shanghai, P. R. China
7. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway and Saolta University Healthcare Group, University College Hospital Galway, Galway, Ireland;
8. Barts Heart Centre, London and Queen Mary University of London, London, UK and Yale University School of Medicine, New Haven, CT, USA
9. Barts Heart Centre, London and Queen Mary University of London, London, UK and Yale University School of Medicine, New Haven CT, USA, United Kingdom
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Methods and results: The TARGET All Comer study is a prospective, multicenter, randomized, non-inferiority trial. A total of 1653 patients were randomly allocated to receive either the Firehawk or XIENCE stent. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization. At 3-year follow-up, TLF occurred in 11.9% in the Firehawk group and 11.5% in the XIENCE group (p=0.84). The event rates of individual components of TLF were comparable for the 2 groups. Landmark analyses between 1 and 3 years showed no significant difference of TLF for the Firehawk versus XIENCE stent. The incidence of very late definite or probable stent thrombosis was 0.8% in the Firehawk group and 1.4% in the XIENCE group (p=0.24).
Conclusions: The 3-year follow-up of the TARGET All Comers study showed comparable safety and efficacy profiles of the biodegradable polymer Firehawk and the durable polymer XIENCE stent.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com